1. Scrip
  2. >>Therapy Areas

New RUBY Results Boost GSK's Blockbuster Bid For Jemperli

 
• By Kevin Grogan

The company’s PD-1 inhibitor Jemperli plus GSK's own PARP Zejula has scored a win in a late-stage endometrial cancer trial that could lead to a key label expansion.

labcoat
• Source: GSK

GSK plc has presented yet more positive data that cements Jemperli's position as the backbone of its oncology portfolio, with a combination of the checkpoint inhibitor and the company's PARP inhibitor Zejula extending survival in patients with endometrial cancer.

The UK major has released topline results from the second part of the Phase III trial called RUBY which evaluated Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel) followed by Jemperli plus Zejula (niraparib) as maintenance therapy in patients with primary advanced or recurrent endometrial cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

More from Anticancer